TELK: Profile for Telik, Inc.

Telik, Inc., a clinical stage drug development company, focuses on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The companys advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the discovery of small molecule drug candidates. The company was founded in 1988 and is based in Palo Alto, California.

Key Statistics

COMPANY WEBSITES

Home Page

Search Yahoo! for:
More on Telik Inc.

CORPORATE GOVERNANCE

Telik Inc.'s Corporate Governance Quotient (CGQ®) as of 6-Nov-09 is better than 71.3% of CGQ Universe companies and 46.6% of Pharmaceuticals, Biotechnology & Life Sciences companies.

Brought to you by Institutional Shareholder Services.

View Financials

KEY EXECUTIVES

	Pay	Exercised
Dr. Michael M. Wick M.D., Ph.D., 63 Chairman, Chief Exec. Officer and Pres	$ 514.00K	$ 120.00K
Ms. Cynthia M. Butitta , 54 Chief Operating Officer, Chief Financial Officer and Principal Accounting Officer	$ 379.00K	$ 116.00K
Mr. William P. Kaplan Esq., 55 VP, Sec. and Gen. Counsel	N/A	N/A
Mr. Marc L. Steuer , 62 Sr. VP of Bus. Devel.	N/A	N/A
Dr. Gail L. Brown M.D., 58 Chief Medical Officer and Sr. VP	N/A	N/A

Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.

View Insiders

Add to Portfolio

Set Alert

Email to a Friend

•

Annual Reports

•

Sector Analysis